sevenTM allows pharmaceutical and biotech companies to validate more candidates, in less time, with higher accuracy, and lower toxicity. Our goal is to enable the design and creation of society changing pharmaceuticals.
Our tools augment and improve the current process of drug discovery R&D teams with minimal disruption. We limit the effort to adopt our tools into the process, while producing meaningful and measurable improvements.
Low population disease therapeutic design remains difficult, and without technological advance, these patients will remain underserved.
We have developed stand alone tools that augment and improve the early drug discovery process. This includes toxicity prediction, protein structure modeling, candidate docking and manufacturability prediction.
Our models gain real-world validation via in-silico/in-vitro feedback loops. We do this by partnering with R&D teams of Pharmaceutical and top researchers to design new candidates to move to clinical trials leveraging our AI-powered drug discovery pipeline.
.png)
%402x.svg)
%402x%20(Light).svg){kind=icon}
